The Registry Study of Genetic Alterations of Melanoma in Taiwan

Plain-language summary

This registry study examines the genetic alterations seen in melanoma patients in Taiwan. It enrolls patients over 18 with a pathologically confirmed melanoma diagnosis across different disease stages. This non-phase study is currently recruiting.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

National Health Research Institutes, Taiwan

Start date

8/22/2022

Estimated completion

12/31/2030

Countries

Taiwan

Related genes

Locations

• Taipei, Taiwan
• Chiayi City, Taiwan
• Kaohsiung City, Taiwan
• Kaohsiung City, Taiwan
• Sindian City, Taiwan
• Taichung, Taiwan
• Taichung, Taiwan
• Taichung, Taiwan
• Tainan, Taiwan
• Taipei, Taiwan
• Taipei, Taiwan
• Taipei, Taiwan
• Taipei, Taiwan
• Taipei, Taiwan
• Taoyuan, Taiwan
• Taoyuan, Taiwan

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

1. Age \> 18 years old
2. Pathologically confirmed melanoma. (Patients with additional malignancies requiring treatment or follow-up are allowed. Only treatment for melanoma should be recorded).
3. ECOG performance status \< 3
4. Cohort 1(early acral melanoma): melanoma, stage I/II; Cohort 2 (locally advanced acral melanoma): melanoma, stage III, resectable; and Cohort 3 (advanced): unresectable / metastatic melanoma, stage III/IV or recurrent melanoma (unresectable). Staging is based on AJCC Cancer Staging System 8th edition). The patients with advanced melanoma with available comprehensive NGS report are included in cohort 4.
5. Willingness to provide archival or newly obtained tumor tissues for this study proposal
6. Life expectancy more than 3 months -
7. Patients fully understand the protocol with the willingness to have regular follow-up

Exclusion Criteria:

1. Inability to cooperate by providing a complete medical history
2. No available tumor tissues for genetic testing (archived tissue sampling more than 5 years from screening date)
3. Undesirable compliance (Mental status is not fit for further treatment or data collection.)